

COHORT PROFILE

Cohort Profile: The Swiss Childhood Cancer Survivor Study

Claudia E Kuehni,^{1*} Corina S Rueegg,¹ Gisela Michel,¹ Cornelia E Rebholz,¹ Marie-Pierre F Strippoli,¹ Felix K Niggli,² Matthias Egger,¹ and Nicolas X von der Weid³ for the Swiss Paediatric Oncology Group (SPOG)[†]

¹Institute of Social and Preventive Medicine (ISPM), Swiss Childhood Cancer Registry, University of Bern, Bern, Switzerland,

²Paediatric Oncology Unit, University Children's Hospital Zürich, Zürich, Switzerland and ³Paediatric Haematology-Oncology Unit, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

*Corresponding author. Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland. E-mail: kuehni@ispm.unibe.ch

[†]The names of the members of the SPOG are provided in the Acknowledgements section.

How did the study come about?

Thanks to continuous improvements in therapy, 5-year survival of childhood cancer in developed countries now exceeds 80%,^{1,2} leading to a growing population of long-term survivors. As the cancer and treatment can cause adverse effects long after the illness has been cured, assessment of long-term quality of life (QOL), somatic, psychological and social outcomes become increasingly important. Although cancer in children is rare, the population impact of late toxicities on disability-adjusted life years is considerable because of the young age at diagnosis.

Up to now, many single-centre studies or clinical trials have been published, but only few large representative long-term follow-up studies exist, including the Childhood Cancer Survivor Studies in the USA (CCSS),³ Canada⁴ and Great Britain (BCCSS).⁵ These studies found increased risks of second malignant neoplasms (SMNs),⁶ mortality^{7,8} and chronic medical problems such as endocrine dysfunctions, cardiovascular problems, stroke or infertility.^{9–11} Psychosocial problems such as depression, anxiety and post-traumatic symptoms have also been reported.^{12,13} Life-long medical follow-up is thus recommended for high-risk patients.^{14,15}

For these reasons, we created a national cohort study of all survivors of childhood and adolescent cancer in Switzerland, the Swiss Childhood Cancer Survivor Study (SCCSS).

What does it cover?

The SCCSS is a nationwide population-based cohort study of all children diagnosed with cancer in Switzerland since 1976, which aims to study long-term consequences of childhood cancer, including

mortality, SMNs, QOL, late somatic, psychological and social effects, health behaviours and health care.

In particular, the SCCSS aims to:

- (i) determine the incidence of late effects of cancer and treatments, including overall and cause-specific mortality, SMNs, somatic toxicities (endocrine disorders, infertility and pregnancy complications, cardiovascular, pulmonary and orthopaedic problems), health-related QOL and psychosocial outcomes including psychological distress, educational and professional attainment;
- (ii) study associations between adverse outcomes and prospectively collected risk factors, including tumour (exact diagnosis, histology, cytogenetics, tumour stage and clinical features at diagnosis), treatment modalities (chemotherapy, radiotherapy, surgery), participation in clinical trials, age, sex, nationality, geographic region and socio-economic position of parents;
- (iii) describe the current health-care use and medical follow-up in survivors, including type of health care, frequency of visits and uptake of recommended screening procedures and
- (iv) describe health-related behaviours and their determinants in survivors compared with the general population.

Who is in the sample?

The Swiss Childhood Cancer Survivor Study is closely linked with the Swiss Childhood Cancer Registry (SCCR; www.childhoodcancerregistry.ch), including all children registered in the SCCR who survived ≥ 5 years.

The SCCR is the population-based cancer registry for all Swiss residents diagnosed <21 years of age with leukaemias, lymphomas, central nervous system (CNS) tumours, malignant solid tumours or Langerhans cell histiocytosis.^{16–20} It was founded in 1976. Case ascertainment is excellent for children aged 0–15 years at diagnosis who are usually treated in one of the nine specialized paediatric cancer centres (Figure 1). Regular comparison of the SCCR with data sets from cantonal cancer registries, Swiss hospital statistics, major pathology laboratories and mortality statistics allows the integration of patients who had not been treated in paediatric cancer centres.

Adolescents aged 16–20 years at diagnosis are also registered in the SCCR. However, coverage of this age group is still unsatisfactory, because only a minority of adolescents in Switzerland are treated in paediatric cancer centres. Instead, care is shared between a large and heterogeneous group of specialists and hospitals, such that not all cases are reported.²¹ The SCCR aims for a complete coverage of adolescents by the year 2015.

By 31 December 2010, the SCCR included information on 5553 Swiss residents with cancer diagnosed at the age of 0–15 years (Table 1). Of these, 2435 (44%) had been diagnosed at the age of 0–4 years, 1423 (26%) at age 5–9 years and 1695 (31%) at age 10–15 years; 3143 (57%) were males and 2410 (43%) females. The most common diagnosis was leukaemias

(34%), followed by CNS tumours (18%), lymphomas (14%), neuroblastoma (7%), soft tissue sarcomas (6%) renal tumours (5%) and bone tumours (5%). In total, 1395 patients (25%) had died.

The SCCSS (Figure 2) is the long-term cohort study of all patients registered in the SCCR who survived ≥ 5 years. For the questionnaire survey 2007–11, only children diagnosed from 1976 to 2003, in the age group of 0–15 years, were included ($N=2738$). From 2011, the study will be extended to include adolescents diagnosed at the age of 16–20 years ($n \approx 1200$), children not treated in a paediatric cancer centre ($n \approx 500$), children diagnosed between 2003 and 2005 ($n=463$) and children who had been registered in the SCCR after December 2003 although diagnosed earlier ($n=160$, Figure 2).

What has been measured?

The data collected for the SCCR and the SCCSS come from three sources:

- (i) clinical data from medical records;
- (ii) routine data on current address, vital status, SMNs and causes of death; and
- (iii) questionnaire surveys and examinations.

These are briefly described below, with details given in Tables 2 and 3.




Figure 1 Population density map of Switzerland showing the location of the nine paediatric cancer centres. Children living in the scarcely populated Alpine region (lower half of map) are treated in Bellinzona, St Gallen, Zurich, Bern or Lausanne

Table 1 Characteristics of the children registered in the Swiss Childhood Cancer Registry, by live status (diagnosed 1976–2010, aged 0–15 years at diagnosis, $N=5553$)

Characteristics	Survivors ($n=4158$) n (%) ^a	Deceased ($n=1395$) n (%) ^a	Total ($n=5553$) n (%) ^a
Age at diagnosis (years)			
0–4.9	1830 (44.0)	605 (43.4)	2435 (43.9)
5–9.9	1059 (25.5)	364 (26.1)	1423 (25.6)
≥10	1269 (30.5)	426 (30.5)	1695 (30.5)
Sex			
Male	2315 (55.7)	828 (59.4)	3143 (56.6)
Female	1843 (44.3)	567 (40.7)	2410 (43.4)
Language region of Switzerland			
German speaking	2946 (71.5)	953 (71.8)	3899 (71.6)
French speaking	1023 (24.8)	307 (23.1)	1330 (24.4)
Italian speaking	152 (3.7)	68 (5.1)	220 (4.0)
Diagnosis (ICCC-3 main groups)			
(I) Leukaemias	1380 (33.2)	507 (36.3)	1887 (34.0)
(II) Lymphomas	664 (16.0)	108 (7.7)	772 (13.9)
(III) CNS tumours	669 (16.1)	349 (25.0)	1018 (18.3)
(IV) Neuroblastoma	239 (5.8)	132 (9.5)	371 (6.7)
(V) Retinoblastoma	120 (2.9)	13 (0.9)	133 (2.4)
(VI) Renal tumours	252 (6.1)	39 (2.8)	291 (5.2)
(VII) Hepatic tumours	35 (0.8)	21 (1.5)	56 (1.0)
(VIII) Bone tumours	173 (4.2)	82 (5.9)	255 (4.6)
(IX) Soft tissue sarcomas	242 (5.8)	101 (7.2)	343 (6.2)
(X) Germ cell tumours	132 (3.2)	14 (1.0)	146 (2.6)
(XI) Other malignant epithelial neoplasms	63 (1.5)	19 (1.4)	82 (1.5)
(XII) Other and unspecified malignant neoplasms	15 (0.4)	3 (0.2)	18 (0.3)
Langerhans cell histiocytosis	174 (4.2)	7 (0.5)	181 (3.3)
Treatment			
Surgery only	601 (15.7)	66 (5.1)	667 (13.0)
Chemotherapy ^b	2030 (53.0)	505 (38.9)	2535 (49.4)
Radiotherapy ^c	991 (25.8)	568 (43.8)	1559 (30.4)
BMT ^d	211 (5.5)	158 (12.2)	369 (7.2)

Adolescents aged 16–20 years at diagnosis are not included in this table, as their coverage in the SCCR is still incomplete. Percentages are based upon available data for each variable.

^aColumn percentages.

^bWithout radiotherapy, may have surgery.

^cWith or without chemotherapy or surgery.

^dWith or without chemotherapy, radiotherapy or surgery.

BMT, bone marrow transplantation; n , number; ICCC-3, International Classification of Childhood Cancer, third edition.

Clinical data from medical records

Information at the time of diagnosis

Children are usually registered in the SCCR within 3 months of diagnosis with standardized forms completed by local data managers of the paediatric cancer centres. In the SCCR, these forms are entered in the database after verification of missing or incorrect

data. For cases not treated in paediatric cancer centres but identified via other sources [cantonal cancer registries, pathology laboratories, mortality statistics for death certificate only (DCO) cases], we migrate information into the SCCR in regular intervals. If not already available, an SCCR data manager extracts relevant information directly from hospital records.




Figure 2 Population of the Swiss Childhood Cancer Registry (SCCR) and the Swiss Childhood Cancer Survivor Study (SCCSS), showing the proportion deceased and response rates to the 2007–11 questionnaire survey. ^aIncludes survivors diagnosed before 1 May 2003 who were included in the SCCR after 2003. ^bMailing to families with survivors aged 5–15 years is performed from October 2010 to April 2011. ICC-3, International Classification of Childhood Cancer, third edition

Information includes baseline demographic data and detailed medical information on the tumour, therapy and response to therapy.^{16,17} Diagnoses are classified according to the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10), the International Classification of Diseases for Oncology, Third Edition (ICD-O3) and the International Classification of Childhood Cancer, third edition (ICCC-3).²²

Clinical follow-up data

As long as children are treated and followed up in paediatric cancer centres (usually 5–10 years from the time of diagnosis), follow-up information on remissions and relapses, changes in treatments and

clinical study participation is extracted annually from patient records by local data managers. Similarly, late effects, SMNs or deaths occurring during this period are registered.

Routine data and linkages

First, current address, vital status and date of death have been updated in a standardized way in 2005–10 for the whole cohort by contacting community registration offices.

Causes of death and death records are identified periodically from the Swiss mortality statistics in the Swiss Federal Statistical Office. The SCCR data are linked with the anonymous mortality statistics via

Table 2 Clinical data, routine data and survey data collected in the SCCSS: detailed description (number of participants with available data in Table 3)

Time frame	Sample addressed	Description/measurements
Clinical data from medical records		
Since 1976	All children in the SCCR	Report of new cases: disease: prior disease, date of diagnosis, exact tumour diagnosis, localization, stage, metastases, cytogenetics, histology Therapy: clinical study participation, treatment protocol, surgery, chemotherapy, radiotherapy, bone marrow transplantation, exact treatment information for non-protocol patients Patient: date of birth, sex, language, nationality, country of birth, address at diagnosis, residence status, contact information, parent's profession, parent's date of birth
Since 1976	All children in the SCCR	Follow up reports from clinics: disease: details on relapse, late effects and second malignancies Therapy: follow-up contacts, lost to follow-up, clinical study participation, details on treatment for first diagnosis, relapse or second malignancy Patient: contact information, life status, date and cause of death, patient's paediatrician or general practitioner
Routine data and linkages		
Since 2005	All children in the SCCR	Updates via communities: vital status, date of death, address history
Since 2005	All deceased children in the SCCR	Linkage with Swiss mortality statistics: causes of death
Since 2009	All linkable children in the SCCR	Linkage with Swiss National Cohort (SNC): environmental exposures and socio-economic situation including all information from Swiss Census dataset (1970, 1980, 1990 and 2000), mortality and migration statistics, and (from 2011) ^a birth records: maternal and paternal education and profession no. of rooms per person and persons per household square metre living space per person area-based socio-economic position index maternal and paternal age child's sex, birthweight, birth length, head circumference
Since 2010	All children in the SCCR	Linkage with cantonal cancer registries: assessment of secondary malignancies: details of tumour diagnosis, date of diagnosis, causes of death
Surveys and examinations		
1994–96	Children diagnosed 1976–89, ≥5 years disease free, ≥2 years off treatment, treated in one of the eight participating SPOG clinics ^b	Medical history and examination: patient's history (medical and psychosocial) Standardized clinical investigation: weight, height, blood pressure, screening audiometry (Phonac®) Laboratory: complete blood count, urinalysis, electrolytes, liver, renal, glomerular and tubular function Endocrinological work up: Tanner's pubertal status, age at menarche, bone age, ft4, TSH, FSH/LH, free β-oestradiol, free testosterone, IGF-1/IGF-BP3 Rest echocardiography and ECG (patients treated with anthracyclines or mediastinal radiation) Pulmonary function test (patients with respiratory symptoms) Intelligence test: WISC-R < 16 years of age, WAIS-R ≥ 16 years of age Socio-economic status of the family: score based on father's profession and mother's schooling
2007–11 (ongoing)	Children diagnosed 1976–2003 ^c who survived ≥5 years	Postal questionnaire (SCCSS): personal information Health-related quality of life Medical care and medication, former disease, somatic and mental health Pregnancy and children (adults)/partner and sexuality (adolescents) Lifestyle and health behaviours Education and social environment

ECG, electrocardiography; FSH, follicle-stimulating hormone; ft4, free thyroxine; IGF-1, insulin-like growth factor 1; IGF-BP3, insulin-like growth factor-binding protein 3; LH, luteinizing hormone; NA, not applicable; No., number; SES, socio-economic status; SNC, Swiss National Cohort; TSH, thyroid stimulating hormone; WISC-R, Wechsler Intelligence Scale for Children-Revised; WAIS-R, Wechsler Adult Intelligence Scale-Revised; SCCSS, Swiss Childhood Cancer Survival Study; SCCR, Swiss Childhood Cancer Registry; SPOG, Swiss Paediatric Oncology Group.

^aChildren diagnosed in 1991–2006 were included in a first linkage study performed in 2009. The linkage will be repeated in 2011 with the entire cohort.

^bParticipating Swiss Paediatric Oncology Group clinics were: Zurich, Bern, Lucerne, Lausanne, Geneva, St Gall, Aarau and Locarno.

^cChildren diagnosed between 1 May 2003 and 31 December 2005 (new 5-year survivors) will receive the questionnaire in 2011.

Table 3 Clinical data, routine data and survey data collected in the SCCSS: available data (*n*) (status December 2010, measurements described in detail in Table 2)

Collection steps	Participants (<i>n</i>)			
	All children in SCCR	Children (5–15)	Adolescents (16–19)	Adults (≥20)
Clinical data from medical records				
Report of new cases	5553	621	470	1647
Follow-up reports from clinics	3726 ^a	580	443	1604
Routine data and linkages				
Updates via communities	5553	621	470	1647
Linkage with Swiss mortality statistics	1395 ^b	NA	NA	NA
Linkage with Swiss National Cohort (SNC)	1867 ^c	191	252	596
Linkage with cantonal cancer registries	Is currently being done for all children in the SCCR (5553)			
Surveys and examinations				
Medical history and examination (1994–96)	478 ^d	NA ^e	NA ^e	453
Postal questionnaire (SCCSS) (2007–11)	1505 ^f	NA ^g	312	1193

n, number; NA, not applicable; SCCSS, Swiss Childhood Cancer Survival Study; SCCR, Swiss Childhood Cancer Registry.

^aThose 1827 without follow-up report include: 1058 deceased, 132 diagnosed within the last year (2010), 637 lost to follow-up.

^bIncludes deceased children only.

^cChildren diagnosed in 1991–2006 were included in a first linkage study performed in 2009. The linkage will be repeated in 2011.

^dEligible were children diagnosed in 1976–1989 who were disease-free for ≥ 5 years.

^eThe 5-year survivors in 1994–96 have meanwhile reached an age of ≥ 20 years.

^fEligible were children diagnosed in 1976–2003 who survived for ≥ 5 years ($N = 2738$, see Figure 2).

^gMailing to families with survivors aged 5–15 years is performed from October 2010 to April 2011.

date of birth, date of death and place of death (the latter two identified via community registration offices). This update, first undertaken in 2005, is being repeated regularly.

Information on peri-natal data, environmental exposures and socio-economic situation for cohort participants and matched controls can be obtained via data linkage with the Swiss National Cohort,²³ a large national cohort study combining data from the Swiss censuses, mortality statistics, migration records and birth records.¹⁸

Secondly, malignant neoplasms are being assessed (in 2010–11) via linkage with Swiss cantonal cancer registries, organized in the National Institute for Cancer Epidemiology and Registration (NICER; www.nicer.org). For linkage, we use a privacy-protecting technique using Bloom filters.²⁴ From 2012, this linkage will be repeated annually to detect new cases.

Surveys and examinations

A first long-term follow-up survey was performed in 1994–96.^{15,25–27} A total of 478 5-year survivors attended follow-up at their former hospital for a standardized medical history, a comprehensive clinical examination and additional investigations focusing on somatic, psychosocial and socio-economic outcomes [e.g. intelligence using the Wechsler Intelligence Scale for Children/Wechsler Adult Intelligence Scale

(WISC/WAIS)²⁸]. Liver, renal, cardiac and lung function were investigated in various subgroups. Participants who had received anthracyclines or mediastinal radiation received a cardiological examination, and patients who had received lung irradiation or chemotherapy with bleomycine or high-dose alkylating agents underwent lung function tests.

A second long-term follow-up survey was performed in 2007–11 (Figure 2), involving a questionnaire to all 5-year survivors who were aged 16–19 years ($N = 470$) or ≥ 20 years ($N = 1647$) at the time of the survey. The mailing to survivors < 16 years ($N = 621$) is ongoing (2010–11).

Methodology of the SCCSS: survey 2007–11

Study logistics

Current addresses, vital status and dates of death for participants of the 2007–11 questionnaire survey were updated via community registration offices (Supplementary Figure S1). All participants with a known address received a study information letter from their former treating hospital. They were asked to indicate if their address had changed, if they required the questionnaire in a language other than

the information letter (German, French or Italian) or if they did not want to participate. After 2 weeks, they received the questionnaire with a pre-paid return envelope. Non-responders were sent another questionnaire 4–6 weeks later and in case of not answering, were contacted by phone. If they felt that the questionnaire was too long, they were offered a short version with key questions.

Self-reported somatic health problems are validated by comparison with medical records from general practitioners or hospitals. This will be done in 2011 for cardiac disease and SMNs, and will be extended to other outcomes in subsequent years. Informed consent for this validation has been collected in the questionnaire.

The SCCSS questionnaire

The questionnaire was created based on those used in the US, Canadian and UK childhood cancer survivor studies^{3–5} to enable international comparison of health outcomes. It contains the following main domains: QOL, somatic health, current medication, health service utilization, psychological distress, fertility, health behaviour and socio-economic information.

In addition to the questions from the US, UK and Canadian questionnaires, we included the Brief Symptom Inventory (BSI) assessing psychological distress,^{29,30} and added more questions on health behaviours and socio-economic information. Unique for the SCCSS is the inclusion of not only the cancer survivors who have reached adulthood, but also younger 5-year survivors.

To account for age-dependent differences, we created three distinct questionnaires: for adult survivors (aged ≥ 20 years), adolescents (aged 16–19 years) and children (aged 5–15 years). Details of the content of the questionnaire are described in Table 4. The questionnaires in German, French and Italian are available on our homepage (<http://www.childhoodcancerregistry.ch/sccss>).

Control data sets for the questionnaire 2007–11

For comparing answers of study participants with healthy controls, we took two different approaches:

- (i) sibling questionnaire—in 2009–11, the same questionnaires (excluding questions on past disease and treatments) are being sent to siblings of the study participants; and
- (ii) population health surveys—in addition to questions derived from other childhood cancer survivor studies,^{3–5} we included questions on QOL, health behaviours and socio-economic outcomes, which were used during the same years in general population health surveys in Switzerland. This allows a straightforward comparison of specific outcomes between survivors and the Swiss general population (Table 4).^{29,31–41}

Study participation and attrition

In the 1994–96 survey, the SCCR contained information on 914 5-year survivors. All patients ($n = 750$) for whom a valid address was found were invited to attend follow-up at their former hospital, and 478 (64%) participated (Table 3).²⁶

In the 2007–11 survey, 2738 eligible survivors were mailed a questionnaire (1647 adults aged 20–49 years at the survey, 470 adolescents aged 16–19 years and 621 children aged 5–15 years; Figure 2). For 134 survivors, we had no valid address, 119 refused and 367 did not answer. Current response rates (31 December 2010) were: 1193 adults (78% of contacted) and 312 adolescents (69% of contacted) (Tables 3 and 5). Mailing of questionnaires to families of children aged 5–15 years and siblings takes place from October 2010 to June 2011. Provisional response rate for the sibling mailing is 451/749 (60%). Respondents to the questionnaire were more likely to be female, German speaking and aged 25–35 years compared with non-respondents (Table 5).

What has been found? Key findings and publications

Somatic outcomes

The first survey (1992–94) collected detailed data on somatic and cognitive outcomes.^{15,25–27} Moderate to severe late effects were found in 211/621 (34%) survivors.²⁶ A subgroup of 140 acute lymphoblastic leukaemia (ALL) survivors was studied in detail.^{25,27} Of those, 21/140 (15%) had moderate to severe late effects, 8 needed special schooling and 14 had problematic psychosocial adjustments. Most survivors suffered from endocrinological abnormalities (20/140, 14%). Problems of the cardiovascular system, lung, liver and digestion were rare (overall 9/140, 6%).²⁵ These findings resulted in the development of Swiss recommendations for long-term follow-up of childhood cancer survivors.¹⁵

In male survivors of acute lymphoblastic leukaemia, we assessed gonadal function and sperm quality. While sex hormone levels were normal, sperm concentration and sperm counts were decreased compared with WHO criteria and healthy controls, suggesting that treatment with moderately dosed chemotherapeutic agents, even without added radiotherapy, might have long-term gonadotoxic effects.⁴²

Prevalence of bronchial asthma, assessed in the 2007–11 survey in young adult survivors, was similar to data published from general population samples in Switzerland.⁴³

Psychological and socio-economic outcomes

In the 2007–11 survey, we assessed psychological distress in young adult childhood cancer survivors and found that average distress scores were similar to normal populations. However, the proportion reporting

Table 4 Structure of the 2007–11 questionnaires (SCCSS), indicating source of questions and available comparison data (three versions of the questionnaire were made for adult, adolescent and child survivors)

Sections of questionnaire	Reference questionnaires and comparison data		
	Adults (aged ≥ 20 years)	Adolescents (aged 16–19 years)	Children (aged 5–15 years)
Personal information	Swiss Census 2000 ³¹ SHS 2007 ³⁴	Swiss Census 2000 ³¹	Swiss Census 2000 ³¹
Health-related QOL	SF-36 ³⁹	SF-36 ³⁹	KidScreen ⁴⁰
Former disease and current health status, medical care and medication	CCSS ³ BCCSS ⁵ BSI ^{a,29,30}	CCSS ³ BCCSS ⁵ BSI ^{a,29,30}	CCSS ³ BCCSS ⁵ SDC ³⁵
Pregnancy and children/partner and sexuality	Own questions BCCSS ⁵	SMASH 2002	NA
Lifestyle and health behaviours	SHS 2007 ³⁴	SHS 2007 ³⁴ SMASH 2002 ³² Tobacco-Monitoring ³³	BALLABEINA ³⁶ GABRIEL ³⁷ KIGGS-Study ³⁸
Formation and social environment	Swiss Census 2000 ³¹ European Social Survey ⁴¹ SHS 2007 ³⁴	Swiss Census 2000 ³¹ SMASH 2002 ³²	Swiss Census 2000 ³¹ SHS 2007 ³⁴

BCCSS, British Childhood Cancer Survivor Study; CCSS, Childhood Cancer Survivor Study; KidScreen, Health-Related Quality of Life Questionnaire for Children and Young People and their Parents; NA, not applicable; SDC, Strength and Difficulties Questionnaire for Children; SF-36, Short Form-36 (version 2); SHS, Swiss Health Survey 2007; SMASH, Swiss Multicentre Adolescent Survey.

^aBrief Symptom Inventory (BSI) with reference data from healthy normal populations and psychotherapy patients from the University of Bern Outpatient Clinic.

high distress was disproportionally large, suggesting that a significant number of survivors might benefit from psychological counselling.³⁰

A considerable proportion of childhood cancer patients had transient problems with schooling, but final educational attainment in adulthood was comparable with the general population. Only CNS tumour survivors and survivors with a relapse had poorer outcomes.⁴⁴

Health behaviours

A healthy lifestyle is important to prevent chronic diseases in the general population and even more relevant for childhood cancer survivors. In 835 young adult survivors and 1670 matched controls, latent class analysis identified four distinct behaviour patterns: 'risk-avoiding'—with a generally healthy behaviour; 'moderate drinking'—with higher levels of physical activity⁴⁵ but moderate alcohol consumption; 'risk-taking'—engaging in several risk behaviours (alcohol, tobacco and marijuana consumption); and 'smoking'—including smoking but not drinking. A considerable proportion of survivors and controls (14 vs 12%) engaged in multiple risk behaviours. Survivors were more likely to be in the 'moderate drinking' and less likely to be in the 'smoking' group, indicating a greater awareness of health compromising effects of tobacco than alcohol. Compared with the general

population,⁴⁶ survivors engaged in binge drinking later in life compared with healthy peers.

Medical care in long-term survivors of childhood cancer

Well-organized medical follow-up is important to detect and treat late effects in survivors. However, we found that only a minority of adult survivors of childhood cancer in Switzerland have regular follow-up, and few received written documentation on their diagnosis, therapy and advice for future medical check-ups.¹⁴ An important barrier for not attending follow-up was the belief that follow-up is not necessary.⁴⁷

On-going and planned studies

New 5-year survivors are integrated continuously into the SCCSS. This makes numbers of the cohort and response rates fluctuate with time.

We plan to send the participants a follow-up questionnaire every 5 years. The next is planned for 2015.

A study funded by the European Union FP7 (PanCareSurFup; running 2011–15) pools data from the SCCSS with data from other European countries, to construct a European cohort of childhood cancer survivors. It aims to describe late mortality, SMNs and cardiac late effects and determine risk factors.

Table 5 Characteristics of the Swiss Childhood Cancer Survivor Study population, for responders and non-responders to the questionnaire survey 2007–11 (5-year survivors currently aged >15 years, diagnosed in 1976–2003, aged 0–15 years at diagnosis, *N* = 2117: 1647 adults and 470 adolescents)

	Responders (<i>n</i> = 1505: 1193 adults and 312 adolescents) <i>n</i> (%) ^a	Non-responders (<i>n</i> = 612: 454 adults and 158 adolescents) <i>n</i> (%) ^a	<i>P</i> -value
Socio-demographic factors			
Sex			
Male	818 (54.4)	389 (63.6)	<0.001
Female	687 (45.7)	223 (36.4)	
Current age (years)			
16–19.9	166 (11.0)	73 (11.9)	0.006
20–24.9	386 (25.7)	181 (29.6)	
25–29.9	407 (27.0)	118 (19.3)	
30–34.9	266 (17.7)	114 (18.6)	
≥ 35	280 (18.6)	126 (20.6)	
Language region of Switzerland			
German speaking	1123 (74.6)	385 (64.5)	<0.001
French speaking	341 (22.7)	182 (30.5)	
Italian speaking	41 (2.7)	30 (5.0)	
Clinical factors			
Diagnosis (ICCC-3 main groups)			
(I) Leukaemias	540 (35.9)	190 (31.1)	0.135
(II) Lymphomas	287 (19.1)	131 (21.4)	
(III) CNS tumours	182 (12.1)	79 (12.9)	
(IV) Neuroblastoma	60 (4.0)	31 (5.1)	
(V) Retinoblastoma	34 (2.3)	20 (3.3)	
(VI) Renal tumours	101 (6.7)	25 (4.1)	
(VII) Hepatic tumours	10 (0.7)	2 (0.3)	
(VIII) Bone tumours	70 (4.7)	24 (3.9)	
(IX) Soft tissue sarcomas	81 (5.4)	41 (6.7)	
(X) Germ cell tumours	47 (3.1)	24 (3.9)	
(XI) Other malignant epithelial neoplasms	19 (1.3)	8 (1.3)	
(XII) Other and unspecified malignant neoplasms	4 (0.3)	1 (0.2)	
Langerhans cell histiocytosis	70 (4.7)	36 (5.9)	
Age at diagnosis (years)			
0–4.9	543 (36.1)	228 (37.3)	0.187
5–9.9	410 (27.2)	184 (30.1)	
≥ 10	552 (36.7)	200 (32.7)	
Time since diagnosis (years)			
5–14.9	347 (23.1)	136 (22.2)	0.453
15–24.9	732 (48.6)	286 (46.7)	
≥ 25	426 (28.3)	190 (31.1)	

(continued)

Table 5 Continued

	Responders (<i>n</i> = 1505: 1193 adults and 312 adolescents) <i>n</i> (%) ^a	Non-responders (<i>n</i> = 612: 454 adults and 158 adolescents) <i>n</i> (%) ^a	<i>P</i> -value
Therapy			
Surgery only	704 (47.1)	282 (46.6)	
Chemotherapy ^b	161 (10.8)	74 (12.2)	
Radiotherapy ^c	517 (34.6)	228 (37.7)	
Bone marrow transplantation ^d	114 (7.6)	21 (3.5)	0.004

Percentages are based upon available data for each variable. *n*, number.

^aColumn percentages.

^bWithout radiotherapy, may have surgery.

^cWith or without chemotherapy or surgery.

^dWith or without chemotherapy, radiotherapy or surgery.

Radiation doses and chemotherapeutic agents received will be studied in detail.

An on-going research programme (2009–12) on follow-up care funded by the Swiss National Science Foundation (SNF) studies different models of follow-up for childhood cancer survivors in Switzerland and Europe. In addition, all survivors in Switzerland who replied in 2007–11 will receive a questionnaire about their needs and desires for follow-up care after childhood cancer and how they would like to see it organized. Oncologists and general practitioners receive a similar questionnaire.^{48–50}

Two projects nested in the SCCSS (from 2011 to 2014; funded by the SNF and the Swiss Cancer League) focus on transition from paediatric to adult follow-up care in Switzerland.

Results from all these studies will provide the basis to develop a standardized model of follow-up for survivors of childhood and adolescent cancer in Switzerland and Europe.

What are the main strengths and weaknesses?

Strengths of the SCCSS are:

- the close link with the national childhood cancer registry and paediatric oncology clinics allows easy access to routine data and clinical information from medical records. Additionally, research findings can promptly be translated into daily practice;
- the high response rate makes results representative for the majority of childhood cancer survivors in Switzerland;
- the SCCSS can easily be extended to assess later outcomes in current survivors and to

include new survivors treated with more recent therapies; and

- results of the SCCSS can be compared with results for representative population-based studies performed simultaneously in Switzerland, with results from siblings and with other childhood cancer survivor studies.

Limitations of the study are:

- the number of survivors of certain rare cancers and specific therapies in Switzerland is small, limiting the ability to study rare outcomes. This limitation can be overcome by international pooling of data, as in the incipient EU FP7 survey; and
- although the first late effects study (1994–96) included a standardized medical examination and measurements, outcomes assessed in 2007–11 were based on self-reports from a questionnaire. However, we will validate important outcomes with medical records.

Can I get hold of the data? Where can I find out more?

The SCCR and the SCCSS are collaborative projects between the Swiss Paediatric Oncology Group (SPOG) and the Institute of Social and Preventive Medicine, University of Bern, Switzerland. Our homepage displays detailed information on methods, results and publications (www.childhoodcancerregistry.ch). Researchers interested in collaborative work can contact the principal investigators (Claudia Kuehni, kuehni@ispm.unibe.ch and Nicolas von der Weid, Nicolas.von-der-Weid@chuv.ch) to discuss planned projects or analyses of existing data. The final decision will be made upon presentation of the project to the Scientific Council of the SPOG.

Supplementary Data

Supplementary Data are available at *IJE* online.

Funding

The SCCR is funded by the Swiss Paediatric Oncology Group, Kinderkrebshilfe Schweiz, Stiftung für krebskranke Kinder Regio Basiliensis and other sponsors. The SCCSS is funded by research grants from the Swiss Cancer League (grant numbers KLS 01605-10-2004, KLS 2215-02-2008, KLS 02631-08-2010); the cancer leagues of the cantons Bern and Zurich; the European Union (7th framework programme, PanCareSurfUp HEALTH-F2-2010-257505); Wyeth Foundation, 'Stiftung zur Krebsbekämpfung'; scholarships from the Swiss National Science Foundation and the Bernese cancer league (PROSPER grant 3233-069348/1 to C.E.K.); SNF scholarship (PA001—117433/1 to G.M.); Ambizione (grant PZ00P3_121682/1 to G.M.); MD-PhD fellowship (SNSF-323 630-133897, KFS-02606-06-2010).

Acknowledgements

We would like to thank all childhood cancer survivors in Switzerland, their parents and siblings for completing the extensive questionnaire and helping in many other ways to conduct this important study. The members of the SPOG Scientific Committee: Prof. Dr Med. R. Ammann, Bern; Dr Med. R. Angst, Aarau; PD Dr Med. M. Beck Popovic, Lausanne; Dr Med. P. Brazzola, Bellinzona; Dr Med. U. Caflisch, Lucerne; Dr Med. J. Greiner, St Gallen; Prof. Dr Med. M. Grotzer, Zurich; Dr Med. H. Hengartner, St Gallen; Prof. Dr Med. T. Kuehne, Basel; Prof. Dr Med. K. Leibundgut, Bern; Prof. Dr Med. F. Niggli, Zurich; Dr Med. L. Nobile Buetti, Locarno; PD Dr Med. A. H. Ozsahin, Geneva; Prof. Dr Med. M. Paulussen, Basel; PD Dr Med. J. Rischewski, Lucerne; PD Dr Med. N. X. von der Weid, Lausanne.

Conflict of interest: None declared.

References

- Gatta G, Zigon G, Capocaccia R *et al.* Survival of European children and young adults with cancer diagnosed 1995-2002. *European J Cancer* 2009;**45**:992-1005.
- Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. *CA-Cancer J Clin* 2010;**60**:277-300.
- Robison LL, Mertens AC, Boice JD. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. *Med Pediatr Oncol* 2002;**38**:229-39.
- Shaw AK, Morrison HI, Speechley KN *et al.* The late effects study: design and subject representativeness of a Canadian, multi-centre study of late effects of childhood cancer. *Chronic Dis Can* 2004;**25**:119-26.
- Hawkins M, Lancashire E, Winter DL *et al.* The British Childhood Cancer Survivor Study: objectives, methods, population structure, response rates and initial descriptive information. *Pediatr Blood Cancer* 2008;**50**:1018-25.
- Olsen JH, Möller T, Anderson H *et al.* Lifelong cancer incidence in 47 697 patients treated for childhood cancer in the nordic countries. *J Natl Cancer I* 2009;**101**:806-13.
- Reulen RC, Winter DL, Frobisher C *et al.* Long-term cause-specific mortality among survivors of childhood cancer. *JAMA* 2010;**304**:172-79.
- Mertens AC, Liu Q, Neglia JP. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. *J Natl Cancer I* 2008;**100**:1368-79.
- Alvarez JA, Scully RE, Miller TL *et al.* Long-term effects of treatments for childhood cancers. *Current Opin Pediatr* 2007;**19**:23-31.
- Oeffinger KC, Mertens AC, Sklar CA *et al.* Chronic health conditions in adult survivors of childhood cancer. *New Engl J Med* 2006;**355**:1572-82.
- Diller L, Chow EJ, Gurney JG *et al.* Chronic disease in the Childhood Cancer Survivor Study Cohort: a review of published findings. *J Clin Oncol* 2009;**27**:2339-55.
- Schultz KAP, Ness KK, Whitton J *et al.* Behavioral and social outcomes in adolescent survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2007;**25**:3649-56.
- Zebrack BJ, Zevon MA, Turk N *et al.* Psychological distress in long-term survivors of solid tumors diagnosed in childhood: a report from the Childhood Cancer Survivor Study. *Pediatr Blood Cancer* 2007;**49**:47-51.
- Rebholz CE, von der Weid NX, Michel G, Niggli FK, Kuehni CE. Follow-up care amongst long-term childhood cancer survivors: a report from the Swiss Childhood Cancer Survivor Study. *Eur J Cancer* 2011;**47**:221-29.
- von der Weid NX, Wagner H. Organisation of follow-up in paediatric oncology. *Eur J Cancer* 2003;**39**:1150-54.
- Mitter V, Michel G, Strippoli MPF *et al.* The Swiss Childhood Cancer Registry. *Annual Report 2009/2010*. Bern: Department of Social and Preventive Medicine, University of Bern, 2011.
- Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE. The Swiss Childhood Cancer Registry: rationale, organisation and results for the years 2001-2005. *Swiss Med Wkly* 2007;**137**:502-9.
- Feller M, Adam M, Zwahlen M *et al.* Family characteristics as risk factors for childhood acute lymphoblastic leukemia: a population-based case-control study. *PLoS ONE* 2010;**5**:e13156.
- Michel G, von der Weid N, Zwahlen M, Redmond S, Strippoli MPF, Kuehni CE. Incidence of childhood cancer in Switzerland: the Swiss Childhood Cancer Registry. *Pediatr Blood Cancer* 2008;**50**:46-51.
- Bouchardy C, Lutz J-M, Kuehni CE. Chapter 5: Childhood cancers. In: *Cancer in Switzerland: Situation and development from 1983 to 1997*. Neuchâtel: BFS, NICER, SCCR, 2011, pp. 72-7.
- Adam M, von der Weid NX, Michel G *et al.* Access to specialized pediatric cancer care in Switzerland. *Pediatr Blood Cancer* 2010;**54**:721-27.
- Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. *Cancer* 2005;**103**:1457-67.

- ²³ Bopp M, Spoerri A, Zwahlen M *et al.* Cohort Profile: The Swiss National Cohort - a longitudinal study of 6.8 million people. *Int J Epidemiol* 2009;**38**:379–84.
- ²⁴ Schnell R, Bachteler T, Reiher J. Privacy-preserving record linkage using Bloom filters. *BMC Med Inform Decis Mak* 2009;**9**:41.
- ²⁵ von der Weid NX. Swiss Pediatric Oncology Group (SPOG). Late effects in long-term survivors of ALL in childhood: experiences from the SPOG late effects study. *Swiss Med Wkly* 2001;**131**:180–87.
- ²⁶ von der Weid NX, Beck D, Caflisch U, Feldges A, Wyss M, Wagner HP. Standardized assessment of late effects in long-term survivors of childhood cancer in Switzerland - results of a Swiss Pediatric Oncology Group (SPOG) Pilot Study. *Int J Pediatr Hem Onc* 1996;**3**:483–90.
- ²⁷ von der Weid NX, Mosimann I, Hirt A *et al.* Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sex-related differences. *Eur J Cancer* 2003;**39**:359–65.
- ²⁸ Littel W. The Wechsler Intelligence Scale for Children. Review of a decade of research. *Psychol Bull* 1960;**57**:132–56.
- ²⁹ Derogatis L. *Brief Symptom Inventory (BSI), Administration, Scoring, and Procedure Manual*. 3rd edn. Minneapolis: Minneapolis National Computer Services, 1993.
- ³⁰ Michel G, Rebholz CE, von der Weid NX, Bergstraesser E, Kuehni CE. Psychological distress in adult survivors of childhood cancer: the Swiss Childhood Cancer Survivor Study. *J Clin Oncol* 2010;**28**:1740–48.
- ³¹ Germann U. *Abschlussbericht zur Volkszählung 2000 [Final report of Census 2000]*. Neuchâtel: Swiss Federal Statistical Office, 2005.
- ³² Jeannin A, Narring F, Tschumper A *et al.* Self-reported health needs and use of primary health care services by adolescents enrolled in post-mandatory schools or vocational training programmes in Switzerland. *Swiss Med Wkly* 2005;**135**:11–18.
- ³³ Keller R, Radtke T, Krebs H, Hornung R. Der Tabakkonsum der Schweizer Wohnbevölkerung in den Jahren 2001 bis 2009. *Tabakmonitoring - Schweizerische Umfrage zum Tabakkonsum [Tobacco consumption of the Swiss population in 2001–2009. Tobacco Monitoring - Swiss survey on tobacco use]*. Zürich: Psychologisches Institut der Universität Zürich, Sozial- und Gesundheitspsychologie, 2010.
- ³⁴ Liebherr R, Marquis J, Storni M, Wiedenmayer G. *Gesundheit und Gesundheitsverhalten in der Schweiz 2007 - Schweizerische Gesundheitsbefragung [Health and health behaviour in Switzerland in 2007 - Swiss Health Survey]*. Neuchâtel: Swiss Federal Statistical Office, 2010.
- ³⁵ Klasen H, Woerner W, Rothenberger A, Goodman R. German version of the Strength and Difficulties Questionnaire (SDQ-German) - overview and evaluation of initial validation and normative results. *Praxis der Kinderpsychol Kinderpsychiatrie* 2003;**52**:491–502.
- ³⁶ Niederer I, Kriemler S, Zahner L *et al.* Influence of a life-style intervention in preschool children on physiological and psychological parameters (Ballabeina): study design of a cluster randomized controlled trial. *BMC Public Health* 2009;**9**:94.
- ³⁷ Moffatt MF, Gut IG, Demenais F *et al.* A large-scale, consortium-based genomewide association study of asthma. *New Engl J Med* 2010;**363**:1211–21.
- ³⁸ Kurth B-M, Kamtsiuris P, Holling H *et al.* The challenge of comprehensively mapping children's health in a nation-wide health survey: design of the German KiGGS-Study. *BMC Public Health* 2008;**8**:196.
- ³⁹ Ware J, Kosinski M, Dewey J. *How to Score Version 2 of the SF36 Health Survey*. Lincoln, RI: QualityMetric Incorporated, 2000.
- ⁴⁰ Ravens-Sieberer U, Gosch A, Abel T *et al.* Quality of life in children and adolescents: a European public health perspective. *Soc Preventiv Med* 2001;**46**:294–302.
- ⁴¹ Davidov E, Schmidt P, Schwartz SH. Bringing values back in: the adequacy of the European Social Survey to measure values in 20 countries. *Public Opin Quart* 2008;**72**:420–45.
- ⁴² Marquis A, Kuehni CE, Strippoli MPF, Kühne T, Brazzola P. Sperm analysis of patients after successful treatment of childhood acute lymphoblastic leukemia with chemotherapy. *Pediatr Blood Cancer* 2010;**55**:208–10.
- ⁴³ Marquis A, Strippoli MPF, Spycher BD, Rebholz CE, von der Weid NX, Kuehni CE. Paracetamol, nonsteroidal anti-inflammatory drugs, and risk of asthma in adult survivors of childhood cancer. *J Allergy Clin Immun* 2011;**127**:270–72.
- ⁴⁴ Kuehni CE, Strippoli MPF, Rueegg CS *et al.* Educational achievement in Swiss childhood cancer survivors compared to the general population. *Cancer* 2012;**118**:1439–49.
- ⁴⁵ Rueegg CS, Rebholz CE, von der Weid NX *et al.* Physical activity levels among Swiss childhood cancer survivors. *Swiss Med Wkly* 2009;**139**:6S.
- ⁴⁶ Rebholz CE, Kuehni CE, Strippoli MPF *et al.* Alcohol consumption and binge drinking in young adult childhood cancer survivors. *Pediatr Blood Cancer* 2012;**58**:256–64.
- ⁴⁷ Michel G, Kuehni CE, Rebholz CE *et al.* Can health beliefs help in explaining attendance to follow-up care? The Swiss Childhood Cancer Survivor Study. *PsychoOncology* 2011;**20**:1034–43.
- ⁴⁸ Michel G, Greenfield D, Absolom K, Eiser C. Satisfaction with follow-up consultations among younger adults treated for cancer: the role of quality of life and psychological variables. *Psychooncology* 2010;**20**:813–22.
- ⁴⁹ Greenfield DM, Absolom K, Eiser C *et al.* Follow-up care for cancer survivors: the views of clinicians. *Brit J Cancer* 2009;**101**:568–74.
- ⁵⁰ Absolom K, Eiser C, Michel G *et al.* Follow-up care for cancer survivors: views of the younger adult. *Brit J Cancer* 2009;**101**:561–67.